drugset / Trial / NCT00036634

A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients

NCT00036634

Phase 1/2 Completed 30 enrolled Gilead Sciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).

Timeline

Start
2002-03
Primary completion
2003-02
Completion
2003-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tenofovir disoproxil fumarate Small molecule 300 mg Oral
Subject tenofovir alafenamide Small molecule 50 mg Oral
Subject tenofovir alafenamide Small molecule 150 mg Oral